The percentage of patients with high TIM‐3 expression was significantly higher in patients with pancreatic cancer than in those with non‐pancreatic cancer (20/55, 36.4% vs. 70/459, 15.3%, p < 0.001 [multivariate]; Table 2). This evidence concerns the gene HAVCR2 and familial pancreatic carcinoma.